3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Non-small Lung Cancer
1
Neoplasms by Site
1
Neoplasms
1
Lung Neoplasms
1
Lung Diseases
1
Carcinoma, Bronchogenic
1
Carcinoma
1
Interventions
Carboplatin
6
Pemetrexed
5
pembrolizumab
3
selpercatinib
2
pralsetinib
2
osimertinib
2
durvalumab
2
camrelizumab
2
Cisplatin
2
taletrectinib
1
repotrectinib
1
motexafin gadolinium
1
exemestane
1
entinostat
1
ceralasertib
1
belinostat
1
belagenpumatucel L
1
alectinib
1
TNFSF10 protein, human
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oncolytic Virotherapy
1
Injections
1
Gemcitabine
1
Fluorouracil
1
Erlotinib Hydrochloride
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Bronchogenic
×
taletrectinib
×
Clear all
NCT06841874
2025-12-24
Tale EAP
Nuvation Bio Inc.
No longer available